The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to provide a more substantial reduction in body size and enhance metabolic markers, pa… Read More